ERBB2 and breast cancer: The result showed that the polymorphism of HER2 655 A>G was significantly correlated with cardiotoxicity, and supported the role of HER2 655 A>G polymorphism as a genetic marker of cardiotoxicity in trastuzumab-induced HER2-positive breast cancer patients.